A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL).

Trial Profile

A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs CNF 2024 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 09 Jun 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Additional lead trial investigator as Chris Storgard identified as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned end date changed from 1 Jan 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top